Lorcaserin induces abdominal fat loss with associated improvements of the circulating metabolome/lipidome and no changes in the myostatin–activin–follistatin– IGF ‐1 axes: A 6‐month long randomized placebo‐controlled clinical trial
Authors' conclusion
Lorcaserin treatment was associated with greater abdominal fat mass loss, favourable lipid profile changes, while MAFI components remained largely unaffected. Lorcaserin may improve cardiometabolic health primarily through reductions in central adiposity.
Study context
- Population
- Adults with obesity
- Participants
- 48 adults
- Comparison
- Lorcaserin vs placebo
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Total body weight · 6 months
- Lorcaserin vs Placebo: P = 0.004
Further findings
| Outcome | P value |
|---|---|
| Total body fat mass | P = 0.031 |
| Abdominal fat mass | P = 0.002 |
- Total body fat mass: reduction; adjusted delta and endpoint comparisons (ANCOVA, baseline BMI)
- Abdominal fat mass: reduction; adjusted delta and endpoint comparisons (ANCOVA, baseline BMI)
Lipidomics
- Primarily lower levels of triglyceride-rich lipoproteins with treatment
MAFI axes components
- No significant changes in linear mixed models
Original publication
Lorcaserin induces abdominal fat loss with associated improvements of the circulating metabolome/lipidome and no changes in the myostatin–activin–follistatin– IGF ‐1 axes: A 6‐month long randomized placebo‐controlled clinical trial. Diabetes Obes Metab. Published 23 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →